Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt

Blood (2019) 134 (Supplement_1): 2871.

https://doi.org/10.1182/blood-2019-123978

Published: 2019

Journal Articles

Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study

Blood (2018) 132 (Supplement 1): 1597.

https://doi.org/10.1182/blood-2018-99-115167

Published: 2018

Journal Articles

Recurrent Mutations of the Exportin 1 Gene ( XPO1 ) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

Fabrice Jardin, MD PhD, Anais Pujals, PhD, Laura Pelletier, PhD, Elodie Bohers, PhD, Vincent Camus, Sylvain Mareschal, Sydney Dubois, Marlène Ochman, MD, Francois Lemonnier, MD, Pierre-Julien Viailly, Philippe Bertrand, PhD, Catherine Maingonnat, Alexandra Traverse-Glehen, Philippe Gaulard, MD PhD, Diane Damotte, MD PhD, Richard Delarue, MD, Corinne Haioun, MD PhD, Yosef Landesman, PhD, William Senapedis, PhD, Christian Argueta, PhD, Gilles Andre Salles, MD PhD, Jean-Philippe Jais, MD PhD, Martin Figeac, PhD, Christiane Copie-Bergman, MD PhD, Thierry Molina, Jean-Michel Picquenot, PhD, Marie Cornic, Thierry Fest, MD PhD, Noel Milpied, Emilie Lemasle, MD, Aspasia Stamatoullas, MD, Peter Moeller, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Christer Sundstrom, MD PhD, Christian Bastard, MD PhD, Hervé Tilly, MD PhD, Karen Leroy, MD PhD

Blood (2015) 126 (23): 129.

https://doi.org/10.1182/blood.V126.23.129.129

Published: 2015

Journal Articles

Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Ian Flinn, Mark Brunvand, MD, Martin JS Dyer, Peter Hillman, Jeffrey Jones, James Lymp, PhD, Mostafa Elhamy, BSc,BA, Gregory Vosganian, Jane Huang, Thomas J. Kipps, MD PD

Blood (2014) 124 (21): 4687.

https://doi.org/10.1182/blood.V124.21.4687.4687

Published: 2014

Journal Articles

Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant

Steven Coutre, MD, Susan O'Brien, MD, John C. Byrd, MD, Peter Hillmen, MB, ChB, PhD, Jennifer R. Brown, Martin JS Dyer, Anthony R. Mato, MD, David B. Miklos, Michael Keating, MBBS, Cathy Zhou, MS, Maria Fardis, PhD MBA, Lori Styles, MD, Samantha Jaglowski, MD MPH

Blood (2014) 124 (21): 4697.

https://doi.org/10.1182/blood.V124.21.4697.4697

Published: 2014

Journal Articles

Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study

Martin JS Dyer, Andrew P Grigg, MBBS FRACP FRCPA MD, Marcos González Díaz, MD PhD, Martin Dreyling, Simon Rule, MD, Guiyuan Lei, PhD, Elisabeth Wassner-Fritsch, PharmD, Günter Fingerle-Rowson, MDPhD, Paula V Marlton, MBBS

Blood (2014) 124 (21): 1743.

https://doi.org/10.1182/blood.V124.21.1743.1743

Published: 2014

Journal Articles

Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study

Valentin Goede, MD, Anja Engelke, MD, Kirsten Fischer, Javier Lopez Jimenez, Alexej Kuzmin, Martin JS Dyer, Katell Le Dû, Anna Marina Liberati, Rudolf Schlag, Anton W Langerak, Matthias Ritgen, Stephan Stilgenbauer, Elina Asikanius, Kathryn Humphrey, Michael K Wenger, Günter Fingerle-Rowson, Michael Hallek, MD

Blood (2014) 124 (21): 3327.

https://doi.org/10.1182/blood.V124.21.3327.3327

Published: 2014

Journal Articles

The Bruton’s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL)

Blood (2014) 124 (21): 3328.

https://doi.org/10.1182/blood.V124.21.3328.3328

Published: 2014

Journal Articles

BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib

Dietrich Sascha, MD, Andreas Pircher, MD, Mindaugas Andrulis, MD, Elena Ellert, MD, Frédéric Peyrade, Clemens-Martin Wendtner, MD, George A Follows, Martin JS Dyer, Thomas Elter, MD, Robert Zeiser, Anita Gaehler, MD, Michael Herrmann, Michael Herold, MDPhD, Claire Dearden, MD, Hanno Glimm, MD, Michael Hallek, MD, Anthony D Ho, MD, Michael Steurer, Thorsten Zenz, MD

Blood (2014) 124 (21): 3634.

https://doi.org/10.1182/blood.V124.21.3634.3634

Published: 2014

Journal Articles

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma

Simon Rule, MD, Nimish Shah, MD, Gilles Andre Salles, MD, PhD, Lionel Karlin, MD, Franck Morschhauser, MD, PhD, Louis Terriou, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Claire Hutchinson, BMedSci, MRCP, FRCPath, Chris Fegan, MBBS, Guillaume Cartron, MD, PhD, Tomasz Knurowski, MD, James G Wright, PhD, Andrew J Saunders, MD, Hideyuki Honda, Bsc, Andrew Mazur, Toshio Yoshizawa, PhD, Kazuhito Kawabata, PhD, Joseph TP Birkett, PhD

Blood (2013) 122 (21): 4397.

https://doi.org/10.1182/blood.V122.21.4397.4397

Published: 2013

Journal Articles

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

Gilles Andre Salles, MD, PhD, Lionel Karlin, MD, Simon Rule, MD, Nimish Shah, MD, Franck Morschhauser, MD, PhD, Louis Terriou, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Claire Hutchinson, BMedSci, MRCP, FRCPath, Chris Fegan, MBBS, Guillaume Cartron, MD, PhD, Tomasz Knurowski, MD, Andrew J Saunders, MD, James G Wright, PhD, Hideyuki Honda, Bsc, Andrew Mazur, Toshio Yoshizawa, PhD, Kazuhito Kawabata, PhD, Joseph TP Birkett, PhD

Blood (2013) 122 (21): 676.

https://doi.org/10.1182/blood.V122.21.676.676

Published: 2013

Journal Articles

Proliferating CLL Cells Express Abundant But Transcriptionally Compromised TP53 Protein

Jesvin J Samuel, BTech, MRes, Alice H Wignall, BSc, Hishyar Najeeb, BVMS, MSc, Aneela Majid, PhD, Sandrine Jayne, PhD, George D Jones, BSc, MSc, D.Phil., Salvador Macip, MD, PhD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath

Blood (2013) 122 (21): 4134.

https://doi.org/10.1182/blood.V122.21.4134.4134

Published: 2013

Journal Articles

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Andrew Grigg, MBBS, FRACP, FRCPA, Marcos González, Martin Dreyling, Simon A. Rule, MD, Guiyuan Lei, Elisabeth Wassner-Fritsch, Michael K. Wenger, MD, Paula Marlton, MBBS, FRACP, FRCPA

Blood (2012) 120 (21): 3686.

https://doi.org/10.1182/blood.V120.21.3686.3686

Published: 2012

Journal Articles

Homeobox NKX2-3 Is Over-Expressed in Human B-Cell Lymphomas and Drives Marginal Zone B-Cell Lymphomagenesis in Mice

Eloy F Robles, PhD, Beatriz Aldaz, MSc, Takashi Akasaka, MD, PhD, Laura Macri Pellizzeri, MSc, Eduardo Martinez-Anso, PhD, Xavier Aguirre, PhD, Felipe Prosper, MD, Idoia Martin-Guerrero, PhD, Victor Segura, PhD, Maria José Calasanz, PhD, Isidro Sanchez-Garcia, MD, Elena Campos-Sanchez, MSc, Cesar Cobaleda, PhD, Charlotte Cresson, MSc, Cyril Broccardo, PhD, Reiner Siebert, Prof., Dr. med., Xabier Sagaert, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Jose A Martinez-Climent, MD, PhD

Blood (2011) 118 (21): 260.

https://doi.org/10.1182/blood.V118.21.260.260

Published: 2011

Journal Articles

Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression

Anne J. Novak, Ph.D., Takashi Akasaka, MD, PhD, Michelle K Manske, Esteban Braggio, PhD, Tammy Price-Troska, Steve Ziesmer, Secreto Frank, Ph.D., Rafael Fonseca, MD, Mamta Gupta, PhD, Mark E Law, Thomas E. Witzig, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Ahmet Dogan, Ellen McPhail, MD, James R Cerhan, MD, PhD, Stephen Ansell

Blood (2011) 118 (21): 1570.

https://doi.org/10.1182/blood.V118.21.1570.1570

Published: 2011

Journal Articles

Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.

Xiaoyan Jiang, MD, PhD, Hannah Grant, PhD, Justin Stebbing, MD, PhD, Letizia Foroni, MD, Charles Craddock, BM, MRCP, MRCPah, MD, Mike Griffiths, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Stephen O'Brien, MD, PhD, Jamshid S. Khorashad, MD, PhD, Gareth Gerrard, MD, PhD, Lihui Wang, MD, PhD, Julie Irving, PhD, Meng Wang, PhD, Loraine Karran, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Donna L. Forrest, MD, Karen Page, MA, PhD, Connie J. Eaves, PhD, Adrian Woolfson, PhD

Blood (2010) 116 (21): 3397.

https://doi.org/10.1182/blood.V116.21.3397.3397

Published: 2010

Journal Articles

A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34 Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development

Stephen M. Ansell, MD, PhD, Takashi Akasaka, MD, PhD, Michelle Manske, Tammy Price-troska, Steven Ziesmer, Esteban Braggio, Rafael Fonseca, Mamta Gupta, Ph.D, Mark E Law, Thomas E. Witzig, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Ahmet Dogan, M.D., Ph.D., Anne J. Novak, PhD

Blood (2010) 116 (21): 1999.

https://doi.org/10.1182/blood.V116.21.1999.1999

Published: 2010

Journal Articles

Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

Blood (2010) 116 (21): 921.

https://doi.org/10.1182/blood.V116.21.921.921

Published: 2010

Journal Articles

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.

Blood (2009) 114 (22): 3433.

https://doi.org/10.1182/blood.V114.22.3433.3433

Published: 2009

Journal Articles

Elevated Expression of GPR34 in Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma and Its Association with Increased Cell Growth, Erk Activation, and AP-1 and CRE-Mediated Transcription.

Anne J Novak, PhD, Takashi Akasaka, Michelle Manske, Tammy Price-Troska, Mamta Gupta, PhD, Thomas E. Witzig, MD, Martin JS Dyer, Ahmet Dogan, PhD, Stephen M Ansell

Blood (2009) 114 (22): 3927.

https://doi.org/10.1182/blood.V114.22.3927.3927

Published: 2009

NARROW

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study

Recurrent Mutations of the Exportin 1 Gene ( XPO1 ) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant

Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study

Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study

The Bruton’s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL)

BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

Proliferating CLL Cells Express Abundant But Transcriptionally Compromised TP53 Protein

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Homeobox NKX2-3 Is Over-Expressed in Human B-Cell Lymphomas and Drives Marginal Zone B-Cell Lymphomagenesis in Mice

Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression

Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.

A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34 Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development

Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.

Elevated Expression of GPR34 in Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma and Its Association with Increased Cell Growth, Erk Activation, and AP-1 and CRE-Mediated Transcription.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only